Research map: Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics in Older Patients With Atrial Fibrillation: A Prospective Cohort Study

Back to the article

Papers in this map

  1. The REDCap consortium: Building an international community of software platform partners · Paul A. Harris · 2019 · 25228 citations · Cited by this paper
  2. Remnant Cholesterol Paradox: Higher Levels Are Associated With Reduced Mortality in Critically Ill Patients With Heart Failure · 2026 · Related
  3. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) · Isabelle C. Van Gelder · 2024 · 2934 citations · Cited by this paper
  4. Cardiovascular Multimorbidity and Associated Mortality Among Medicare Beneficiaries Dually Eligible for Medicaid · 2026 · Related
  5. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH · Scott S. Kaatz · 2015 · 1424 citations · Cited by this paper
  6. Association of Weighted Composite Score of Long‐Term Variability of Vascular Risk Factors From Childhood With Midlife Cognitive Function: The Bogalusa Heart Study · 2026 · Related
  7. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban · Wolfgang Mueck · 2013 · 625 citations · Cited by this paper
  8. Hypothermia and Stem Cells Confer Limited Protection to Mammillary Bodies in a Neonatal Mouse Model of Hypoxia‐Ischemia · 2026 · Related
  9. Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban · Inna Y. Gong · 2013 · 202 citations · Cited by this paper
  10. Life's Essential 8: Essential for Brain and Cognitive Health · 2026 · Related
  11. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics · Sophie Testa · 2015 · 197 citations · Cited by this paper
  12. Multi‐Omics Analysis for Pathogenesis and Candidate Therapeutic Target in Thoracic Aortic Aneurysms · 2026 · Related
  13. Epidemiology of Atrial Fibrillation · Juqian Zhang · 2021 · 147 citations · Cited by this paper
  14. Impaired Microvascular Reactivity to Passive Limb Movement After Stroke Is Improved by a Single Session of Ischemic Conditioning · 2026 · Related
  15. Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis · Zhi‐Chun Gu · 2019 · 96 citations · Cited by this paper
  16. Role of Lipin‐1 in Macrophage‐Mediated Atherosclerosis: Is It Atherogenic or Atheroprotective? · 2026 · Related
  17. Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants · Arnar Bragi Ingason · 2021 · 89 citations · Cited by this paper
  18. Functional Status Indicators and Long‐Term Mortality Following Elective Coronary Artery Bypass Grafting: A Multicenter Cohort Study · 2026 · Related
  19. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users · Jaakko Lähteenmäki · 2021 · 58 citations · Cited by this paper
  20. Left Ventricular Unloading With Impella Versus Intra‐Aortic Balloon Pump in Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation · 2026 · Related
  21. Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation · Yan Wang · 2021 · 39 citations · Cited by this paper
  22. Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis · Xiuehui Chen · 2023 · 31 citations · Cited by this paper
  23. Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients · Chao‐Lun Lai · 2017 · 29 citations · Cited by this paper
  24. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation · Tingting Wu · 2023 · 27 citations · Cited by this paper
  25. ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban · Hamin Kim · 2023 · 23 citations · Cited by this paper
  26. Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients · Alessandra M. Campos‐Staffico · 2022 · 22 citations · Cited by this paper
  27. Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants · Ha-Young Yoon · 2022 · 18 citations · Cited by this paper
  28. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation · Dmitry Alekseevich Sychev · 2022 · 18 citations · Cited by this paper
  29. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice · Dmitry Alekseevich Sychev · 2022 · 17 citations · Cited by this paper
  30. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study · Qian Xiang · 2023 · 17 citations · Cited by this paper
  31. Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation · Xiaoye Li · 2023 · 15 citations · Cited by this paper
  32. Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban · Ming Zhao · 2021 · 14 citations · Cited by this paper
  33. Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non‐valvular atrial fibrillation · Dan Zhang · 2022 · 11 citations · Cited by this paper
  34. Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis · Mariana Vieira Morau · 2024 · 5 citations · Cited by this paper
  35. Anticoagulants: From chance discovery to structure-based design · Noel C.Y. Chan · 2025 · 5 citations · Cited by this paper
  36. Evaluation of the rivaroxaban-influenced effect of ABCB1 and CYP3A5 gene polymorphisms on prothrombin time in patients after total hip or knee replacement surgery · Dmitry Alekseevich Sychev · 2018 · 4 citations · Cited by this paper
  37. [Application of electronic data acquisition system REDCap in large natural population-based cohort studies]. · Xiangyu Gao · 2020 · 4 citations · Cited by this paper
  38. Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art Review · Ling Wang · 2025 · 4 citations · Cited by this paper
  39. How can we reduce thrombotic and hemorrhagic events in elderly patients with atrial fibrillation? · Ilaria Palumbo · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)